EG-MCV4 for meningococcal infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Oct 2025: Trial registered, NCT07204457
  2. 15 Oct 2025: Trial started, NCT07204457

The trials

NCT07204457: Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

State
Under way
Phase
Phase 2 and Phase 3
People
1,123 planned
Started
15 Oct 2025
Primary completion
Sep 2026
Arms
EG-MCV4 (Test group 1), EG-MCV4 (Test group 2)
Results
None posted
  1. 2 Oct 2025: Trial registered
  2. 15 Oct 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.